HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low - What's Next?

Key Points

• HUTCHMED hit a new 52-week low, trading as low as $12.82 and last at $13.31 on volume ~51,600, remaining below its 50- and 200-day simple moving averages (both ≈ $14.5).
• The company reported a large earnings miss for the quarter — EPS $0.01 vs. $2.50 expected and revenue $135.4M vs. $290.5M estimated — which likely pressured the stock.
• Analysts are mixed: the consensus rating is "Hold" with a $16.88 price target, and recent notes include a Bank of America target cut to $20 while Jefferies upgraded to a "strong-buy."

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) hit a new 52-week low during trading on Friday . The stock traded as low as $12.82 and last traded at $13.3060, with a volume of 51557 shares. The stock had previously closed at $13.44.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Bank of America dropped their target price on shares of HUTCHMED from $21.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, March 10th. Wall Street Zen cut HUTCHMED from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Jefferies Financial Group raised HUTCHMED to a "strong-buy" rating in a research note on Monday, January 19th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of HUTCHMED in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, HUTCHMED has a consensus rating of "Hold" and a consensus price target of $16.88.

HUTCHMED Stock Down 1.6%

The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The company's fifty day simple moving average is $14.49 and its 200 day simple moving average is $14.56.

HUTCHMED (NASDAQ:HCM - Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The business had revenue of $135.42 million for the quarter, compared to analyst estimates of $290.50 million. Sell-side analysts predict that HUTCHMED will post 0.41 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. lifted its holdings in HUTCHMED by 131.5% in the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company's stock worth $103,000 after buying an additional 4,378 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company's stock valued at $234,000 after purchasing an additional 698 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of HUTCHMED by 12.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company's stock valued at $273,000 after purchasing an additional 1,873 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company's stock valued at $310,000 after purchasing an additional 3,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company's stock valued at $342,000 after purchasing an additional 5,538 shares during the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

About HUTCHMED

HUTCHMED NASDAQ: HCM is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED's integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED's commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.